Pure Global

Evaluation of the Efficacy and Safety of DM934 Versus Théalose on Eye Dryness - Trial NCT06245421

Access comprehensive clinical trial information for NCT06245421 through Pure Global AI's free database. This phase not specified trial is sponsored by Horus Pharma and is currently Recruiting. The study focuses on Dry Eye. Target enrollment is 80 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
Device Trial
NCT06245421
Recruiting
Device Trial
device
Trial Details
ClinicalTrials.gov • NCT06245421
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Evaluation of the Efficacy and Safety of DM934 Versus Théalose on Eye Dryness
Multicentric, Randomized, Comparative Clinical Study on the Evaluation of the Efficacy and Safety of DM934 Versus Théalose on the Treatment of Moderate to Severe Ocular Dryness

Study Focus

Dry Eye

DM934

Interventional

device

Sponsor & Location

Horus Pharma

Aix-en-Provence,Bordeaux,Gdańsk,Valladolid,London, France,Poland,Spain,United Kingdom

Timeline & Enrollment

N/A

Mar 07, 2024

Dec 01, 2024

80 participants

Primary Outcome

Cornea and conjunctiva staining (Oxford score)

Summary

This study is a multicentric, comparative, randomized, investigator-blinded, parallel group
 study to demonstrate the non-inferiority of DM934 in comparison with Théalose in terms of
 cornea and conjunctiva staining (Oxford score) on patients with moderate to severe ocular
 dryness, after 35 days of treatment

ICD-10 Classifications

Ocular pain
Avulsion of eye
Other corneal deformities
Corneal ulcer
Dry mouth, unspecified

Data Source

ClinicalTrials.gov

NCT06245421

Device Trial